CancerGRACE

cancergrace.org

 

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Dacomitinib, Erlotinib vs Bevacizumab, Gefitinib+Chemo

July 22, 2019

0 Comments
Login to view comments. Click here to Login
Lung